德克斯潘醇对老鼠中罗诺诱导的帕金森病模型的神经保护作用
Cansu Bilister Egilmez1, Burcu Azak Pazarlar1, Mumin Alper Erdogan1
1Faculty of Medicine, Department of Physiology, Izmir Katip Celebi University, Izmir, Turkey.
Neuroscience letters
|December 1, 2023
概括
德克斯潘醇在帕金森病 (PD) 的老鼠模型中显示出神经保护作用. 它减少了神经元损失,氧化损伤和炎症,这表明PD患者的潜在治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,其特征是多巴胺能神经元的损失.
- 轮激素诱导的模型被广泛用于研究PD的发病过程,包括氧化应激和神经炎症.
- 德克斯潘醇是一种维生素B5衍生物,在之前的研究中已经显示出抗氧化特性.
研究的目的:
- 在帕金森病的罗诺诱导大鼠模型中研究德克桑的神经保护潜力.
- 为了评估德克桑醇对条体中抗氧化和抗炎性标记物的作用.
- 评估德克桑醇对多巴胺基神经元存活率和运动功能的影响.
主要方法:
- 在雄性大鼠中建立了罗农诱导的帕金森病模型.
- 在28天的时间里,小鼠接受了德克桑醇 (500毫克/千克) 或盐水治疗.
- 通过对多巴胺能神经元的免疫组织化学分析和测量条状MDA,TNF-α和HVA水平来评估神经保护.
主要成果:
- 德克斯潘醇治疗显著增加了条形体中多巴胺基神经元的数量和强度.
- 在德克斯潘醇组中,马隆迪阿尔海德 (MDA) 和瘤亡因子-α (TNF-α) 的水平显著降低.
- 多巴胺代谢物荷莫瓦尼利克酸 (HVA) 的水平在德克桑醇组显著增加.
结论:
- 德克斯潘醇在罗诺诱导的帕金森病模型中表现出显著的神经保护作用.
- 这些效应通过减少氧化应激,神经炎症和纹状体中神经元损失来调解.
- 德克斯潘醇作为帕金森病的潜在治疗剂具有前景.
相关概念视频
Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557


